We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+12.45%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.3B
AUM Growth
+$126M
Cap. Flow
+$12.8M
Cap. Flow %
0.98%
Top 10 Hldgs %
49.24%
Holding
85
New
28
Increased
16
Reduced
23
Closed
13

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$20.9M
2
ADMA icon
ADMA Biologics
ADMA
+$20.2M
3
UTHR icon
United Therapeutics
UTHR
+$19.9M
4
MRK icon
Merck
MRK
+$19.5M
5
ELV icon
Elevance Health
ELV
+$18.9M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$31.9M
2
DHR icon
Danaher
DHR
+$31.9M
3
HUM icon
Humana
HUM
+$27.8M
4
MOH icon
Molina Healthcare
MOH
+$25.5M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
26
DELISTED
Centessa Pharmaceuticals
CNTA
$16.2M 1.24%
666,196
+321,224
+93% +$5.71M
OSCR icon
27
Oscar Health
OSCR
$9.27B
$15.5M 1.19%
820,642
+85,609
+12% +$1.41M
RVMD icon
28
Revolution Medicines
RVMD
$38.8B
$15.5M 1.19%
+331,069
New +$13M
VERA icon
29
Vera Therapeutics
VERA
$2.31B
$14.9M 1.15%
+513,685
New +$11.9M
SPY icon
30
State Street SPDR S&P 500 ETF Trust
SPY
$806B
$14.1M 1.09%
21,210
+4,081
+24% +$2.62M
IWM icon
31
PUT
iShares Russell 2000 ETF
IWM
$81.5B
$13.7M 1.05%
+56,700
New +$13M
INDV icon
32
Indivior Pharmaceuticals
INDV
$4.42B
$13.5M 1.04%
561,526
-794,405
-59% -$16.6M
VEEV icon
33
Veeva Systems
VEEV
$33.5B
$12.4M 0.95%
+41,503
New +$11.7M
MRUS
34
DELISTED
Merus
MRUS
$12.3M 0.95%
130,742
-53,140
-29% -$3.46M
BSX icon
35
CALL
Boston Scientific
BSX
$70.2B
$11.9M 0.92%
+122,000
New +$12.6M
AKRO
36
DELISTED
Akero Therapeutics
AKRO
$11.8M 0.91%
248,079
-18,088
-7% -$876K
REGN icon
37
Regeneron Pharmaceuticals
REGN
$78.2B
$11.2M 0.86%
+19,890
New +$11.2M
IRTC icon
38
iRhythm Holdings
IRTC
$4.1B
$11.2M 0.86%
64,998
-23,159
-26% -$3.68M
CMPS
39
Compass Pathways
CMPS
$1.52B
$9.53M 0.73%
1,662,836
-116,423
-7% -$523K
WAT icon
40
Waters Corp
WAT
$36.8B
$9.22M 0.71%
30,751
-12,338
-29% -$3.72M
VRNA
41
DELISTED
Verona Pharma
VRNA
$8.58M 0.66%
80,416
– –
INBX icon
42
Inhibrx
INBX
$1.21B
$8.07M 0.62%
239,644
-4,617
-2% -$114K
NBIX icon
43
Neurocrine Biosciences
NBIX
$16.9B
$8.04M 0.62%
57,246
+44,425
+347% +$6.02M
TEVA icon
44
Teva Pharmaceuticals
TEVA
$40.2B
$7.21M 0.55%
356,818
-882,028
-71% -$15.5M
ARQT icon
45
Arcutis Biotherapeutics
ARQT
$3.24B
$6.79M 0.52%
360,460
-562,915
-61% -$8.88M
CGON icon
46
CG Oncology
CGON
$6.1B
$6.36M 0.49%
+157,874
New +$4.59M
AMLX icon
47
Amylyx Pharmaceuticals
AMLX
$2.24B
$5.93M 0.46%
436,156
-296,100
-40% -$2.79M
COO icon
48
Cooper Companies
COO
$14.5B
$5.1M 0.39%
+74,363
New +$5.27M
RYTM icon
49
Rhythm Pharmaceuticals
RYTM
$7.05B
$4.86M 0.37%
+48,162
New +$4.47M
VKTX icon
50
Viking Therapeutics
VKTX
$3.8B
$4.82M 0.37%
183,538
+145,809
+386% +$4.35M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q3 2025 Portfolio in Review

As of Q3 2025, PFM Health Sciences held 85 positions worth $1.3B, up 11% from $1.17B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

PFM Health Sciences's Q3 2025 filing shows 28 new, 16 increased, 23 reduced and 13 closed positions. Its largest new stake was Universal Health Services: 116,260 shares worth $23.8M. The largest sale was Eli Lilly, an estimated $31.9M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 95% a quarter earlier.

  • PFM Health Sciences's largest Q3 2025 buy was Universal Health Services: 116,260 shares worth $23.8M.
  • PFM Health Sciences added most to United Therapeutics in Q3 2025, an estimated $19.9M increase.
  • PFM Health Sciences's biggest Q3 2025 reduction was Eli Lilly, cutting an estimated $31.9M.
  • PFM Health Sciences fully exited Danaher in Q3 2025, selling an estimated $31.9M.
  • PFM Health Sciences's ten largest holdings make up 49% of its $1.3B portfolio in Q3 2025.
  • PFM Health Sciences opened 28 new positions and closed 13 in Q3 2025.
  • PFM Health Sciences's portfolio value rose 11% quarter-over-quarter to $1.3B.

Based on PFM Health Sciences's 13F filing for Q3 2025, filed 14 Nov 2025.